Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study- - -Topline results for Phase 3.
Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 09, 2021 16:01 ET | Source: Brickell Biotech, Inc. Brickell Biotech, Inc. Boulder, Colorado, UNITED STATES
Initiated U.S. pivotal Phase 3 clinical program (Cardigan I and II studies) evaluating sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis
Cardigan I study exceeds 50% enrollment with topline results from both studies anticipated in the fourth quarter of 2021
Commercial launch of sofpironium bromide gel, 5% (ECCLOCK
®
) underway in Japan by development partner, Kaken Pharmaceutical Co., Ltd. (Kaken)
BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilit